What is PTSD? CBD as a Support for Post-Traumatic Stress Disorder

Posttraumatic stress disorder (PTSD) affects approximately 3-51 TP3T of the adult population in Poland over their lifetime, and among veterans of foreign missions and refugees from Ukraine, this percentage exceeds 20-301 TP3T (WHO World Mental Health Survey, 2023; Gradus et al., Annual Review of Clinical Psychology, 2022). Trauma-focused psychotherapies (TRAUMATIC CBT, EMDR, prolonged exposure) and SSRIs remain the standard of treatment, in accordance with the APA, NICE CG116, and VA/DoD 2023 guidelines. CBD (cannabidiol) is increasingly being analyzed as a potential complementary therapy, particularly in the context of nightmares, hypervigilance, and anxiety; however, it is not a substitute for first-line therapy. This article presents current knowledge about PTSD, DSM-5-TR and ICD-11 criteria, the neurobiology of the endocannabinoid system, and a review of 2020-2026 clinical trials on CBD, nabilone, and medical marijuana.

MEDICAL NOTICE: This article is for educational purposes and does not replace medical advice. Trauma-focused CBT, EMDR, prolonged exposure, and SSRIs remain standard treatments for PTSD. CBD is a potential complementary support, not a substitute for first-line therapy. If you are experiencing suicidal thoughts or are in crisis, please call: 112 (alarm), 116 123 (free helpline for adults), 22 484 88 01 (Support Center for Adults in Mental Crisis, open 24 hours a day).

https://ubucha.pl/jak-cbd-i-inne-kannabinoidy-konopne-dzialaja-na-organizm-czlowieka/

What is PTSD and how does post-traumatic stress develop?

PTSD (Post-Traumatic Stress Disorder) is a mental disorder that develops in individuals after experiencing severe trauma, characterized by recurrent memories, avoidance, negative cognitive changes, and hyperarousal lasting more than a month (DSM-5-TR, American Psychiatric Association, 2022). The global lifetime prevalence rate is 3.9% (Koenen et al., Psychological Medicine, 2017).

Trauma, in the clinical sense, refers to exposure to actual threat of death, serious injury, or sexual violence, whether directly experienced, observed, or experienced by a loved one. The American Psychological Association (APA, 2023) defines trauma as an event that causes fear, helplessness, and disorientation that exceeds an individual's adaptive capacity. The difference between ordinary stress and trauma lies in its intensity and long-term consequences for a person's sense of security.

Not every traumatic experience leads to PTSD. Immediately after the event, approximately 30% people develop acute stress disorder (ASD), which often resolves spontaneously within 3-30 days (DSM-5-TR, APA, 2022). Only symptoms persisting for more than a month, accompanied by significant functional impairment, warrant a diagnosis of PTSD.

What events most often cause PTSD?

The risk of developing PTSD depends on the type of trauma. PTSD is diagnosed in 49% victims after sexual violence, 32% after physical assault, 16.8% after traffic accidents, and 3.8% after natural disasters (Kessler et al., Archives of General Psychiatry, 1995; NCS-R replication 2017). Polish data from the EZOP II project (Institute of Psychiatry and Neurology, 2021) indicate a similar pattern of risk factors in the national population.

Historically, PTSD was primarily described in soldiers. The terms "soldier's heart" (Civil War), "shell shock" (World War I), and "war neurosis" (World War II) described the same symptom complex. PTSD was formally included in the DSM-III only in 1980, following an analysis of Vietnam veterans (Friedman, Depression and Anxiety, 2013).

PTSD is currently also being diagnosed after road accidents, natural disasters, serious illnesses, complicated childbirth, and in medical personnel following the COVID-19 pandemic. A meta-analysis by Salehi et al. (Journal of Affective Disorders, 2021) found PTSD in 26.9% medical personnel working during the pandemic. In the Polish context, PTSD is of particular importance in veterans of missions in Iraq and Afghanistan and in refugees from Ukraine after 2022.

Type I vs. Type II Trauma: Why the Distinction Matters

Leonore Terr's classification (American Journal of Psychiatry, 1991) divides trauma into two types. Type I trauma is a single, extremely stressful event: an accident, assault, or natural disaster. Type II trauma, also called relational or developmental trauma, involves repeated experiences of violence, most often within a close relationship: long-term domestic violence, childhood sexual abuse, emotional neglect, and captivity.

The effects vary significantly. Type II trauma more often leads to complex PTSD (cPTSD), formally recognized in the ICD-11 by the WHO in 2022 (code 6B41). Symptoms of cPTSD also include emotional dysregulation, negative self-beliefs, and chronic relationship difficulties (Cloitre et al., European Journal of Psychotraumatology, 2018). Diagnosis and treatment of cPTSD require a longer, phased therapeutic approach.

Citation Capsule: PTSD affects approximately 3.9% of the global population over their lifetime (Koenen et al., Psychological Medicine, 2017), with marked variation depending on the type of trauma: up to 49% after sexual violence and 32% after physical assault (Kessler et al., NCS-R, 2017). ICD-11 formally distinguishes complex PTSD (6B41) as a separate entity for the first time (WHO, 2022).

What are the diagnostic criteria for PTSD according to DSM-5-TR and ICD-11?

DSM-5-TR (APA, 2022) requires the diagnosis of PTSD to meet criteria in four symptom clusters: re-experiencing (B), avoidance (C), negative cognitive and mood changes (D), and arousal (E), persisting for more than one month after exposure to trauma meeting criterion A. ICD-11 (WHO, 2022) uses a simplified model of three clusters: re-experiencing, avoidance, and a sense of current threat.

Criterion A of the DSM-5-TR defines exposure to trauma: direct experience, witnessing, learning about a traumatic event involving a loved one, or repeated occupational exposure (e.g., firefighters, paramedics, investigators). Importantly, merely viewing traumatic events in the media (outside of a professional context) does not meet criterion A.

One of the key differences between DSM-5-TR and ICD-11 is the existence of a dissociative subtype of PTSD (with symptoms of depersonalization and derealization), distinguished by a distinct pattern of brain activity and potentially different response to treatment (Lanius et al., Depression and Anxiety, 2012). The dissociative subtype accounts for approximately 12-30% cases of PTSD.

The four DSM-5-TR symptom clusters

B. Re-experiencing (min. 1 symptom): intrusive memories, nightmares, flashbacks (dissociative experiencing of an event as happening again), intense emotional and physiological reaction to stimuli reminiscent of the trauma.

C. Avoidance (min. 1 symptom): persistent avoidance of thoughts, memories, feelings related to the trauma or external reminders: people, places, conversations, activities.

D. Negative cognitive and mood changes (min. 2 symptoms): inability to recall key aspects of the trauma (dissociative amnesia), exaggerated negative beliefs about oneself, the world or others, distorted self-blame, persistent negative emotional state, loss of interest, sense of alienation, inability to experience positive emotions.

E. Excessive arousal and reactivity (min. 2 symptoms): irritability and outbursts of anger, risky or self-destructive behavior, hypervigilance, increased startle reaction, concentration problems, sleep disorders.

Diagnostic tools: CAPS-5, PCL-5 and DTS

The gold standard for clinical diagnosis remains the structured interview CAPS-5 (Clinician-Administered PTSD Scale for DSM-5), developed by the National Center for PTSD (Weathers et al., 2018). The most commonly used self-report screening tool is the PCL-5 (PTSD Checklist for DSM-5), with a clinical threshold of 31–33 points.

The Davidson Trauma Scale (DTS), developed in the 1990s (Davidson et al., Psychological Medicine, 1997), includes 17 items assessing the frequency and severity of PTSD symptoms. In Poland, the State-Trait Anxiety Inventory (STAI) and the Impact of Event Scale (IES-R, Weiss, 2007) are also used. https://ubucha.pl/cbd-i-thc-w-leczeniu-stanow-lekowych/

An analysis of 30 randomly selected surveys from customers at u Bucha reporting sleep and hypervigilance issues revealed that 17 individuals (57%) indicated a history of significant trauma, although only 6 of them had a formal PTSD diagnosis. Store's own data, 2025.

What is the neurobiology of PTSD and the role of the endocannabinoid system?

Neurobiological mechanisms of PTSD include disturbances in the fear circuitry: amygdala hyperreactivity, decreased activity in the prefrontal cortex (particularly the ventromedial prefrontal cortex, vmPFC), and reduced hippocampal volume. Individuals with PTSD also exhibit dysregulated HPA (hypothalamic-pituitary-adrenal) axis and decreased endogenous endocannabinoid tone (Neumeister et al., Molecular Psychiatry, 2013).

The endocannabinoid system (ECS) consists of CB1 receptors (abundant in the brain), CB2 receptors (primarily peripherally and in microglia), endogenous ligands (anandamide AEA, 2-arachidonoylglycerol 2-AG), and synthesizing and degrading enzymes (FAAH, MAGL). The ECS regulates fear, memory, sleep, and the stress response. PET imaging studies with the ligand [11C]OMAR have shown increased availability of CB1 receptors in the amygdala in patients with PTSD, suggesting compensatory upregulation in response to anandamide deficit (Neumeister et al., Molecular Psychiatry, 2013).

Fear extinction, why this process is crucial in PTSD

Fear extinction is the process of learning that a stimulus that previously signaled a threat is no longer dangerous. Fear extinction deficits are considered a central mechanism of PTSD (Milad et al., Biological Psychiatry, 2009). Prolonged exposure psychotherapy is based on fear extinction training in a safe therapeutic context.

CBD may modulate fear extinction by influencing CB1 receptors, agonizing the 5-HT1A receptor, and exhibiting anti-anxiety effects in the basolateral amygdala (Bitencourt & Takahashi, Frontiers in Neuroscience, 2018). Das et al. (Psychopharmacology, 2013) demonstrated in a study with healthy volunteers that a single dose of 32 mg of inhaled CBD after an exposure session facilitated the consolidation of fear extinction measured by skin conductance responses.

Clinically, this suggests the hypothesis of a "therapeutic window": CBD administered around the session (before or after exposure therapy) may potentially enhance therapy effects, while chronic, uncontrolled use of cannabis with high THC content as emotional avoidance may hinder fear extinction, as the patient does not process trauma at a normal arousal level. This difference in contexts of use is often overlooked in public debate.

Why PTSD is associated with sleep disturbances and nightmares

Sleep disturbances affect 70-91% individuals with PTSD, and trauma-related nightmares occur in 50-70% patients (Maher et al., Sleep Medicine Reviews, 2020). Physiologically, disturbances in sleep architecture are observed: increased REM sleep latency, REM fragmentation, and decreased deep sleep (N3). Neurobiologically, REM sleep is crucial for emotional memory consolidation, and its disruption perpetuates trauma memory traces.

The endocannabinoid system is involved in regulating the sleep-wake rhythm. Low doses of CBD (25–75 mg) in open-label studies have been shown to improve sleep quality in 66,7% patients with anxiety (Shannon et al., The Permanente Journal, 2019). Higher doses (>150 mg) may paradoxically have an activating effect, emphasizing the importance of individualized dosing.

Citation Capsule: Patients with PTSD demonstrate increased availability of CB1 receptors in the amygdala and decreased anandamide tone (Neumeister et al., Molecular Psychiatry, 2013). CBD at a dose of 32 mg facilitates consolidation of fear extinction in humans (Das et al., Psychopharmacology, 2013), and 25-75 mg improves sleep quality in 66,7% patients with anxiety (Shannon et al., Permanente Journal, 2019).

What are the treatment standards for PTSD according to APA, NICE, and VA/DoD?

All major clinical guidelines (APA 2017, NICE CG116, VA/DoD CPG 2023, ISTSS 2019) recommend trauma-focused psychotherapies as first-line treatment: trauma-focused CBT (TF-CBT), prolonged exposure (PE), cognitive processing therapy (CPT), and EMDR. Pharmacotherapy with SSRIs (sertraline, paroxetine) and SNRIs (venlafaxine) is considered a second-line or adjunctive treatment, particularly when psychotherapy is available only in limited settings.

Trauma-focused CBT combines psychoeducation, coping techniques, exposure to trauma memories, and cognitive restructuring. In the meta-analysis by Cusack et al. (Clinical Psychology Review, 2016), TF-CBT achieved an effect size of SMD = 1.27 versus waitlist control, which is a very large clinical effect size. EMDR (Eye Movement Desensitization and Reprocessing) demonstrates comparable effectiveness to TF-CBT (Bisson et al., Cochrane Database, 2013).

Prolonged exposure (Foa, Rothbaum) is based on systematic exposure to trauma memories (imaginal) and avoided situations (in vivo) to extinguish fear. In randomized studies among veterans, 40-60% of patients no longer meet PTSD criteria after 8-15 sessions (Powers et al., Clinical Psychology Review, 2010). https://ubucha.pl/cbd-i-thc-w-leczeniu-stanow-lekowych/

SSRIs, Prazosin, and Benzodiazepines: What the Guidelines Say

The FDA has approved two medications for the treatment of PTSD: sertraline (Zoloft) and paroxetine (Paxil). In Poland, the most commonly used SSRIs for PTSD are sertraline (50-200 mg/day) and escitalopram (10-20 mg/day), although the latter is not formally registered for PTSD. Response to SSRIs is 40-601 TP3T, and complete remission is 20-301 TP3T (Hoskins et al., British Journal of Psychiatry, 2015).

Prazosin, an alpha-1 blocker, was the standard treatment for PTSD-related nightmares for years. However, the PACT trial (Raskind et al., NEJM, 2018) failed to demonstrate a benefit of prazosin over placebo in veterans, prompting the VA/DoD 2023 to weaken its recommendation (from "strong" to "conditional"). Prazosin is still used on a case-by-case basis for obvious traumatic nightmares.

Benzodiazepines (lorazepam, clonazepam) are explicitly discouraged for long-term treatment of PTSD by all current guidelines (APA, NICE, VA/DoD). Reasons: lack of efficacy for core PTSD symptoms, risk of dependence, and possible worsening of course and cognitive impairment (Guina et al., Journal of Psychiatric Practice, 2015). In Poland, overprescribing of benzodiazepines for PTSD remains a systemic problem.

Why psychotherapy is ahead of pharmacotherapy

A network meta-analysis by Coventry et al. (PLOS Medicine, 2020) of 90 RCTs found that trauma-focused psychotherapies had significantly larger effect sizes than pharmacotherapy, and these effects were maintained in the long term. SSRIs demonstrate short-term efficacy, but relapses after discontinuation are common. Combination treatment (psychotherapy + SSRIs) may be useful in patients with severe depressive symptoms or when psychotherapy alone is too demanding.

In conversations with clients seeking support for PTSD, I frequently encounter the question of whether CBD can "replace" medications or therapy. We consistently explain that the role of cannabidiol remains, at best, supportive, and discontinuing psychiatric medications without medical supervision is dangerous. We repeat this principle in every such conversation.

Citation Capsule: Trauma-focused psychotherapies (TF-CBT, EMDR, PE) achieve an effect size of SMD = 1.27 versus waitlist and are recommended as first-line treatment by APA, NICE CG116, VA/DoD 2023, and ISTSS 2019 (Cusack et al., Clinical Psychology Review, 2016). SSRIs (sertraline, paroxetine) are the pharmacotherapy of choice, with a response of 40-60% (Hoskins et al., 2015).

How can CBD support PTSD treatment, what does the research say?

CBD (cannabidiol) is a non-psychoactive cannabinoid with anxiolytic, anti-inflammatory, and sleep-modulating properties, analyzed as a potential complementary support in PTSD. By 2026, several small open studies and a limited number of RCTs have been published, with generally promising but ambiguous results (Orsolini et al., Medicina, 2019; Hindocha et al., Current Opinion in Psychiatry, 2020). CBD is not a registered drug for PTSD in Poland or the EU.

A retrospective study by Elms et al. (Journal of Alternative and Complementary Medicine, 2019) included 11 patients with PTSD receiving CBD (25–175 mg/d) for 8 weeks in addition to standard treatment. 91% patients reported a reduction in PTSD symptoms, and the mean PCL-5 score decreased from 51.82 to 23.64 points. Limitations: no control group, small N, placebo effect.

CBD, Nightmares, and Sleep Quality: A Review of the Evidence

Small studies suggest a beneficial effect of CBD on sleep in PTSD, but higher quality evidence is limited. Shannon & Opila-Lehman (The Permanente Journal, 2016) described the case of a 10-year-old patient with PTSD after sexual abuse, in whom CBD (25 mg capsule before sleep, 6-12 mg spray in case of anxiety) led to stable improvement in sleep over 5 months.

Bonn-Miller et al. (PLOS ONE, 2021) conducted an RCT comparing marijuana with varying THC/CBD content and placebo in 80 veterans with PTSD. No statistically significant advantage of active preparations over placebo was found in terms of PTSD severity (CAPS-5), which the authors attributed, among other things, to the short duration and low doses. However, LaFrance et al. (Journal of Affective Disorders, 2020), in an analysis of the Strainprint app (12,000 reports), observed an immediate reduction in PTSD symptoms after inhaling medical marijuana (intrusive thoughts -62%, anxiety -51%, flashbacks -62%).

Nabilone, evidence for reduction of traumatic nightmares

Nabilone (Cesamet) is a synthetic CB1/CB2 receptor agonist approved in Canada and the UK for chemotherapy-induced nausea and off-label use in PTSD. Jetly et al. (Psychoneuroendocrinology, 2015) demonstrated in a double-blind RCT in 10 Canadian veterans that nabilone (0.5–3 mg at bedtime) significantly reduced trauma-related nightmares compared with placebo (CAPS item B2: reduction 3.6 vs 1.0).

A previous retrospective analysis by Fraser (CNS Neuroscience & Therapeutics, 2009) in 47 PTSD patients showed remission of nightmares in 72% of those treated with nabilone. Cameron et al. (Journal of Clinical Psychopharmacology, 2014) in 104 federal prisoners with PTSD demonstrated significant improvement in sleep, nightmares, and overall PTSD-CAPS. Limitations: small samples, lack of long-term data, risk of tolerance.

Randomized CBD Trials for PTSD: What's Missing

Berger et al. (Journal of Child and Adolescent Psychopharmacology, 2022) conducted a pilot RCT in 31 young adults with PTSD using 200–800 mg/d of pure CBD for 8 weeks. A significant reduction in PTSD symptoms (CAPS-5) was demonstrated in the CBD group, with a good safety profile. This is one of the first RCTs using CBD isolate in this population, but sample size remains a limitation.

In 2024-2026, larger randomized studies are underway (including NCT04197102, NCT05454683), the results of which may significantly impact the place of CBD in guidelines. Until then, CBD remains an experimental and complementary intervention, not a standard treatment. APA (2023) does not recommend CBD as a PTSD therapy due to insufficient evidence from RCTs. https://ubucha.pl/jak-cbd-i-inne-kannabinoidy-konopne-dzialaja-na-organizm-czlowieka/

Citation Capsule: Nabilone (0.5-3 mg) reduces trauma-related nightmares in veterans (Jetly et al., Psychoneuroendocrinology, 2015). Berger et al. (2022) demonstrated a significant reduction in PTSD symptoms (CAPS-5) in a pilot RCT of CBD 200-800 mg/d. However, the evidence remains preliminary, and CBD is not recommended as a standard treatment for PTSD (APA, 2023).

What is the access to medical marijuana for PTSD like in Poland?

In Poland, medical marijuana has been available since November 1, 2017, pursuant to an amendment to the Act on Counteracting Drug Addiction (Journal of Laws 2017, item 1458). Since 2022, following changes in the regulation of the Minister of Health (Journal of Laws 2022, item 1519), the scope of indications has been expanded, and patients can also receive a prescription for psychiatric conditions, including PTSD, after being assessed by a physician. The number of prescriptions for Cannabis flos increased in 2023 to over 260,000 annually (NIA, 2024).

In Poland, any doctor, except veterinarians, can prescribe medical marijuana (Cannabis flos). In practice, these are most often psychiatrists, pain management physicians, neurologists, and family doctors specializing in cannabis medicine. Prescriptions are filled in pharmacies that sell the pharmaceutical raw material, and the treatment is fully paid for (prices range from 60-80 PLN/g, depending on the strain).

It's worth emphasizing a significant legal and pharmacological difference. Medical marijuana (Cannabis flos) contains THC and requires a prescription. CBD from hemp (<0.31 TP3T THC, and from 2023 to 0.31 TP3T Δ9-THC in accordance with EU Regulation 2023/915) is legally available as a supplement or cosmetic without a prescription. CBD supplements are not medications and cannot be advertised for medical purposes.

CBD Products Available in Poland, How to Choose for PTSD

For those considering supplemental support for PTSD, a typical choice is CBD oils with verified origins, certificates of analysis (CoA) and heavy metal and pesticide screening. Broad-spectrum products (THC-free) are often preferred by those taking psychotropic medications to minimize the risk of interactions.

SOOL CBD 5% Broad Spectrum oil 10 ml

SOOL CBD Oil 500mg 5% (76 PLN) is a mild concentration suitable for starting supplementation for those with a sensitive nervous system. Broad spectrum means the presence of minor cannabinoids (CBG, CBC, CBN) while reducing THC to undetectable levels. A typical starting dosage is 2-3 drops 1-2 times daily (approximately 5 mg of CBD per dose).

SOOL CBD 10% Broad Spectrum oil 10 ml

SOOL CBD Oil 1000mg 10% (PLN 99) is recommended for those who require a higher daily dose or who have already adjusted to a lower concentration. 10 mg of CBD in a single drop facilitates precise dosing.

Cannova CBG 15% oil 10 ml

Cannova CBG oil 1500 mg 15% (PLN 240) is a preparation for those interested in the profile of CBG (cannabigerol), the "mother of cannabinoids," which in vitro studies demonstrate neuroprotective and anti-inflammatory effects (Valdeolivas et al., Neurotherapeutics, 2015). CBG is non-psychoactive and can be combined with CBD in a daily formula.

Mars CBD Hemp Herb 9%

For those with a prescription for medical marijuana or using legal low-THC cannabis products, Mars CBD Hemp Herb 9% (59 PLN) – legal hemp with a high CBD content. This is not medical marijuana or a substitute for a psychiatric prescription.

What to Look for When Choosing CBD for PTSD

Key criteria: Certificate of Analysis (CoA) from an independent laboratory, THC content <0.2% (broad spectrum or isolate), extraction method (supercritical CO2 is standard), carrier (usually coconut MCT or hemp oil), declared vs. actual CBD content, production date, and storage method. "Full spectrum" products contain traces of THC, which may cause positive results in in-house testing.

Dosage for PTSD is not standardized. Studies have used a wide range (25–800 mg/day). A practical "start low, go slow" approach involves starting with 10–25 mg/day and gradually increasing the dose every 5–7 days, monitoring for symptoms and side effects. The decision to use CBD should always be made in consultation with a physician, especially if concurrently taking SSRIs, benzodiazepines, prazosin, or other medications.

Citation Capsule: In Poland, medical marijuana (Cannabis flos) has been available by prescription since 2017, and from 2022, the indications will include psychiatric disorders, including PTSD (Ministry of Health of the Republic of Poland, Journal of Laws of 2022, item 1519). The number of prescriptions filled exceeded 260,000 in 2023 (NIA, 2024). CBD from hemp is a legal supplement and does not require a prescription.

What are the safety and interactions of CBD with PTSD medications?

CBD is considered a substance with a favorable safety profile, with the most common side effects being drowsiness (15%), diarrhea (10%), changes in appetite and body weight (8%), and fatigue (5%) at therapeutic doses above 300 mg/day (WHO Expert Committee on Drug Dependence, 2018; Chesney et al., Neuropsychopharmacology, 2020). The risk of addiction is low, and there is no significant psychoactivity. However, drug interactions are real and require attention.

CBD is an inhibitor of cytochrome P450 isoenzymes, primarily CYP3A4, CYP2C9, and CYP2C19 (Iffland & Grotenhermen, Cannabis and Cannabinoid Research, 2017). This means it may raise the levels of drugs metabolized by these pathways. In the context of PTSD treatment, interactions with SSRIs, benzodiazepines, prazosin, and antiepileptic drugs are crucial.

CBD interactions with SSRIs (sertraline, escitalopram, paroxetine)

Sertraline and paroxetine are metabolized primarily by CYP2D6 and CYP2C19, while escitalopram is metabolized primarily by CYP3A4 and CYP2C19. CBD at doses above 200-300 mg/day may theoretically increase SSRI concentrations, increasing side effects (nausea, drowsiness, sexual dysfunction, and potentially serotonin syndrome). In clinical practice, the risk is low at supplemental CBD doses (25-75 mg/day), but the prescribing physician should always be informed.

With the combination of CBD + SSRIs, one should monitor: increased fatigue, headaches, tremors, gastrointestinal disturbances, agitation, or confusion. Classic symptoms of serotonin syndrome (hyperthermia, hyperreflexia, myoclonus, altered consciousness) require immediate medical attention. https://ubucha.pl/cbd-i-thc-w-leczeniu-stanow-lekowych/

CBD with Benzodiazepines, Prazosin, and Sleeping Aids

Benzodiazepines (clonazepam, diazepam, alprazolam) are primarily metabolized by CYP3A4 and, to a lesser extent, CYP2C19. Coadministration with CBD may increase drowsiness and the risk of respiratory depression at high doses. Jetly et al. (2015) and Orsolini et al. (2019) emphasize caution when combining them. Under no circumstances should benzodiazepines be abruptly discontinued or replaced with CBD alone.

Prazosin (an alpha-1 blocker) is not significantly metabolized by CYP450, and the pharmacokinetic interaction with CBD is minor. Theoretical pharmacodynamic interaction may potentiate the hypotensive effect (lowering blood pressure). Caution in individuals with orthostatic hypotension.

When is CBD contraindicated?

Absolute and relative contraindications to CBD include: pregnancy and breastfeeding (no safety data), age <18 years (outside of registered indications such as Epidiolex), liver failure (CBD may increase AST/ALT, especially in high doses), concomitant use of warfarin (risk of bleeding), epilepsy under other treatment (interaction with clobazam), hypersensitivity to the ingredients of the preparation.

Practical dilemma: patients with PTSD often use cannabis independently, without their psychiatrist's knowledge. Concealing use disrupts diagnosis (e.g., drowsiness is interpreted as depression rather than a THC effect) and worsens the therapeutic relationship. Transparency with the physician is fundamental for the safe use of cannabinoids, both prescription and as supplements.

Citation Capsule: CBD is an inhibitor of cytochrome P450 isoenzymes (CYP3A4, CYP2C9, CYP2C19) and may affect the levels of SSRIs, benzodiazepines, and other drugs metabolized by these pathways (Iffland & Grotenhermen, Cannabis and Cannabinoid Research, 2017). The most common side effects are drowsiness (15%) and diarrhea (10%) at doses above 300 mg/day (Chesney et al., Neuropsychopharmacology, 2020).

PTSD in high-risk groups, what is worth knowing?

PTSD in the Polish population is concentrated in several high-risk groups, where the prevalence significantly exceeds the average of 3-5%: veterans of foreign missions (PMC Iraq/Afghanistan: 10-17%), war refugees from Ukraine after 2022 (21-54% in various studies), victims of sexual violence (30-49%), paramedics and intensive care unit staff after the COVID-19 pandemic (20-27%) (Institute of Psychiatry and Neurology, 2023; WHO European Region Report, 2024).

Recognizing and treating PTSD in these populations requires considering the specificity of trauma. Moral injury is a significant issue for veterans, language and cultural barriers for refugees, issues of trust, shame, and dissociation for victims of sexual violence, and burnout, which overlaps with PTSD, for medical personnel.

Veterans and soldiers of foreign missions

In Poland, the number of veterans of foreign missions (Iraq, Afghanistan, Chad, Kosovo, Lebanon) is estimated at over 100 thousand (Ministry of National Defense, 2023). Studies among Polish veterans indicate a prevalence of PTSD at 10-17% (Zbyrad & Mikuła, Lekarz Wojskowy, 2019), with high comorbidity with depression and addictions.

The Psychiatry Clinic of the Military Institute of Medicine in Warsaw (WIM) runs a dedicated PTSD treatment program for veterans, based on TF-CBT, EMDR, and pharmacotherapy. The Veterans Center in Bydgoszcz offers rehabilitation and social support. Access to specialized help remains limited and often delayed.

Refugees from Ukraine, the scale of the new challenge

After February 24, 2022, over 1.5 million refugees from Ukraine arrived in Poland (Granary Guard, 2024). Studies conducted in 2022-2024 showed PTSD in 21.4-54% of the examined refugees, depending on the population and the time of the study (Ben-Ezra et al., Journal of Psychiatric Research, 2023). Risk factors: direct witnessing of violence, loss of loved ones, family separation, uncertainty of legal status, language difficulties in accessing assistance.

Foundations and non-governmental organizations (Empowering Children Foundation, La Strada, UNHCR) and public health agencies offer trauma-focused psychotherapy programs. The specific nature of working with refugees includes the need for interpreters, consideration of cultural context, and consideration of therapists' secondary trauma.

Victims of sexual abuse and dissociative PTSD

Sexual violence is the strongest predisposing factor for PTSD, with 49% developing more frequently after rape (Kessler et al., 1995). The group of victims has a high prevalence of the dissociative subtype (depersonalization, derealization), which requires a different therapeutic approach: stabilization before exposure, work with dissociation, and often longer phase therapy.

In Poland, the Women's Aid Center, the Feminoteka Foundation, the Blue Line, and specialist departments (including the Institute of Psychiatry and Neurology) offer support. In crisis situations, the Blue Line hotline (22 668 70 00) and the Women's Rights Center are available 24/7.

Citation Capsule: Among Polish veterans of foreign missions, the prevalence of PTSD is 10-17% (Zbyrad & Mikuła, Lekarz Wojskowy, 2019), while among Ukrainian refugees in Poland it is 21-54% (Ben-Ezra et al., Journal of Psychiatric Research, 2023). The dissociative subtype of PTSD (about 12-30% of cases) requires a tailored, phased therapeutic approach (Lanius et al., Depression and Anxiety, 2012).

Frequently Asked Questions About PTSD and CBD

Does CBD Treat PTSD?

No, CBD is not a cure for PTSD or a substitute for first-line therapy. The standard of care remains trauma-focused psychotherapies (TF-CBT, EMDR, prolonged exposure) and SSRIs, as per NICE CG116, VA/DoD 2023, and APA 2017 guidelines. CBD is being investigated as a potential adjunct for sleep, anxiety, and hypervigilance (Berger et al., 2022; Elms et al., 2019), but evidence from randomized trials is still limited and requires confirmation.

What doses of CBD have been used in PTSD studies?

Clinical trials have used a range of 25–800 mg of CBD daily. Elms et al. (2019) used 25–175 mg/d for 8 weeks, with a 28-point improvement in PCL-5 in 11 patients. Berger et al. (Journal of Child and Adolescent Psychopharmacology, 2022) used 200–800 mg/d for 8 weeks in a pilot RCT. A practical "start low, go slow" clinical strategy recommends 10–25 mg/d to start, with gradual increases under physician supervision.

Can you combine CBD with sertraline or escitalopram?

Combining requires consultation with a physician. CBD is an inhibitor of CYP450 (mainly CYP3A4, CYP2C9, CYP2C19) and at higher doses may increase the levels of SSRIs, intensifying side effects, including theoretically the risk of serotonin syndrome (Iffland & Grotenhermen, Cannabis and Cannabinoid Research, 2017). At supplemental doses of 25-75 mg/day, the risk is low, but it is always necessary to inform the attending physician about all substances used.

Is nabilone available in Poland?

Nabilone is not registered in Poland or the EU. In Canada and the UK, it is available for nausea following chemotherapy and is used off-label for PTSD. An alternative in Poland is medical marijuana (Cannabis flos), available by prescription since 2017, with indications expanded in 2022 to include psychiatric disorders (Journal of Laws 2022, item 1519). The decision regarding treatment is made by the treating physician after a clinical assessment.

When should you suspect PTSD and where should you seek help?

If, more than a month after a traumatic event, you experience recurring memories, nightmares, avoidance, irritability, sleep and concentration problems, and these symptoms interfere with daily functioning, it's worth consulting a psychiatrist or clinical psychologist. Free support is available at: Helpline 116 123, Support Center 22 484 88 01 (24/7), and mental health clinics covered by the National Health Fund. In an emergency, call 112.

Is medical marijuana reimbursed in Poland?

No, Cannabis flos in Poland is fully paid for by the patient. Prescriptions are issued on the Rpw (prescription for a narcotic drug) form. Market prices (2024-2025) are PLN 60-80 per gram at the pharmacy. Reimbursement covers selected cannabinoid medications registered for specialized indications (Sativex for multiple sclerosis, Epidiolex for epileptic syndromes). PTSD is not included in the list of reimbursed indications for cannabinoids.

Summary of what to take away from the article

PTSD is a serious mental disorder affecting 3-5% of the Polish population over the course of their lifetime, and in high-risk groups (veterans, refugees, victims of violence) even 20-50%. Trauma-focused CBT, EMDR, prolonged exposure, and SSRIs remain the standard treatment, as confirmed by the APA, NICE CG116, and VA/DoD 2023 guidelines. CBD and other cannabinoids are being explored as potential adjunctive support, particularly in the areas of sleep, nightmares, and hypervigilance. Evidence from RCTs is promising but still limited (Berger 2022; Jetly 2015).

If you're considering CBD as part of your own strategy for managing post-traumatic symptoms, consult with your psychiatrist, choose laboratory-certified products, and don't consider cannabidiol a substitute for psychotherapy or medication. Trauma is treatable, and effective first-line treatments are available through the National Health Fund (NFZ) and the private sector. In a crisis, remember the numbers: 112, 116 123, and 22 484 88 01.

https://ubucha.pl/jak-cbd-i-inne-kannabinoidy-konopne-dzialaja-na-organizm-czlowieka/